Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
The Combination of Tacrolimus and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04747080
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
- Conditions
- Lymphoblastic LeukemiaAcute Lymphoblastic Leukemiaph+ Acute Lymphoblastic Leukemia
- Interventions
- Drug: Inotuzumab ozogamicinDrug: DasatinibDrug: DexamethasoneDrug: Methotrexate for InjectionDrug: MethotrexateDrug: VincristineDrug: PonatinibProcedure: Allogenic Stem Cell Transplantation
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 25
- Registration Number
- NCT04747912
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- General Practitioners Research Institute
- Target Recruit Count
- 17
- Registration Number
- NCT04746430
- Locations
- 🇳🇱
GPRI, Groningen, Netherlands
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
- Conditions
- Recurrent MedulloblastomaRecurrent Ependymoma
- Interventions
- Drug: IrinotecanDrug: TemozolomideDrug: BevacizumabDrug: Omburtamab I-131Drug: LiothyronineDrug: SSKIDrug: anti-emeticsDrug: DexamethasoneDrug: AntipyreticDrug: Antihistamine
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 62
- Registration Number
- NCT04743661
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Liposomal Bupivacaine Plus Bupivacaine Peripheral Nerve Blockade Versus Ropivacaine Plus Dexamethasone Peripheral Nerve Blockade for Arthroscopic Rotator Cuff Repair
- Conditions
- Rotator Cuff TearsShoulder Pain
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Hospital for Special Surgery Florida
- Target Recruit Count
- 92
- Registration Number
- NCT04737980
- Locations
- 🇺🇸
HSS Florida, West Palm Beach, Florida, United States
Bioequivalence Study of Prednisolone and Dexamethasone
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 24
- Registration Number
- NCT04733144
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
- Conditions
- Prostate CancerMetastatic Castration Resistant Prostate CancerMetastatic Castration-sensitive Prostate Cancer
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04729114
- Locations
- 🇺🇸
Northwest Medical Specialties, Tacoma, Washington, United States
🇺🇸First Urology, Jeffersonville, Indiana, United States
🇺🇸Garden Sate Urology, Morristown, New Jersey, United States
Low-dose Intravenous Dexamethasone at Different Times as Adjunvants for Brachial Plexus Blocks
- Conditions
- Shoulder SurgeryAnalgesiaDexamethasoneIntravenous Drug UsageBrachial Plexus BlockTime
- Interventions
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Shanghai Jiao Tong University Affiliated Sixth People's Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT04714112
- Locations
- 🇨🇳
Shanghai Jiaotong University affiliated Shanghai Sixth People's Hospital, Shanghai, China
Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 110
- Registration Number
- NCT04707534
- Locations
- 🇺🇸
University of Oklahoma Medical Center, Oklahoma City, Oklahoma, United States
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 1
- Registration Number
- NCT04700176
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.